RecruitingNCT06474533
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
Sponsor
Thomas Hope
Enrollment
199 participants
Start Date
Jun 21, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a single center study investigating the use of Fluoroethyltyrosine (FET) in the detection of brain tumors. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize grade of glial neoplasms.
Eligibility
Min Age: 4 Years
Inclusion Criteria9
- Presence or suspicion of intracranial neoplasm in two populations:
- Population 1: Participants after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on MRI.
- Three sub-populations will be considered:
- Recurrent metastatic lesions.
- Recurrent high-grade gliomas (Grades 3 and 4).
- Recurrent low-grade gliomas (Grade 2).
- Population 2: Participants prior to primary treatment with planned biopsy or surgical resection.
- Age \> 3 years.
- Participants in other clinical trials will be eligible for this study including patients undergoing surgery guided by 5-aminolevulinic acid.
Exclusion Criteria3
- Participants with known incompatibility to PET or Computerized tomography (CT)/magnetic resonance imaging (MRI) scans.
- Participants unlikely to comply with study procedures, restrictions and requirements and judged by the Investigator to be unsuitable for study participation.
- Sedation or anesthesia can be used for participants who cannot tolerate the exam.
Interventions
DRUGFluorethyltyrosine (18-F)
Given intravenously (IV)
PROCEDUREPositron Emission Tomography (PET)
Undergo Imaging Procedure
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06474533